Protocol Ledger

NCT07400029 · Phase II · RECRUITING

A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia

Interventional Phase II clinical trial protocol NCT07400029 sponsored by Memorial Sloan Kettering Cancer Center in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-03 Enrollment: 40 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07400029
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)40 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07400029
Protocol FieldVerified Registry Value
NCT IdentifierNCT07400029
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment40 participants (ESTIMATED)
Registered Start Date2026-02-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI